MedPath

Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase

Phase 2
Terminated
Conditions
Chronic Myeloid Leukemia in Chronic Phase
Interventions
Registration Number
NCT00451035
Lead Sponsor
Novartis Pharmaceuticals
Brief Summary

This study will evaluate the efficacy and safety of LBH589B in adult patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
29
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Panobinostat (LBH589)LBH589Participants were administered panobinostat 20 milligram (mg) orally once a day (OD) three times a week as part of a 4 week (28 day) treatment cycle. Panobinostat were administered at the same time each morning with 8oz/240 milliliter (ml) of water after a fasting period of at least two hours (water was allowed). Participants could continue treatment until they experienced unacceptable toxicity or disease progression.
Primary Outcome Measures
NameTimeMethod
Major (Complete/Partial) Cytogenetic Response (MCyR) RateFrom Start of the Study up to End of Study (approximately up to 19 Months)

The CyR, based on the percentage of Ph+ metaphases by karyotype analysis on a bone marrow aspirate, was ideally assessed from a minimum of 20 metaphases in each bone marrow sample. The CyR was defined as: major response including complete (CCyR; 0% Ph+ metaphases) or partial (PCyR; 1 to 35% Ph+ metaphases), minor (36 to 65% Ph+ metaphases), minimal (66 to 95% Ph+ metaphases) or none (96 to 100% Ph+ metaphases).

Secondary Outcome Measures
NameTimeMethod
Area Under the Plasma Concentration (AUC0-24) of PanobinostatPre-dose, and 0.25, 1-2, 3-4, 24, and 48 hours post-dose on Day 1

Area under the curve (AUC) is defined as the area under concentration-time curve as a measure of drug exposure. The area under the plasma concentration-time curve from time zero to 24 hours.

Duration of Major (Complete/Partial) Cytogenetic Response (MCyR) RateFrom Start of the Study up to End of Study (approximately up to 19 Months)

The duration of response was defined as the time between the first documented response to the date of discontinuation due to progressive disease (PD) or death.

Complete Hematologic Response (CHR) RateFrom Start of the Study up to End of Study (approximately up to 19 Months)

CHR was defined by meeting all criteria: white blood cell count \< 10 x 109/L, platelet count \< 450 x 109/L, myelocytes and metamyelocytes in peripheral blood \< 5%, basophils in peripheral blood ≤ 5%, no myeloblasts or promyelocytes in peripheral blood, and no evidence of extramedullary involvement.

Complete Cytogenetic Response (CCyR) and Overall (Complete/Partial/Minor/Minimal) Cytogenetic Response (OCyR) RatesFrom Start of the Study up to End of Study (approximately up to 19 Months)

Cytogenetic response was assessed by bone marrow assessment based on the percentage of Ph+ metaphases by karyotype analysis on a bone marrow aspirate, was ideally assessed from a minimum of 20 metaphases in each bone marrow sample.

Major (MMR) and Complete (CMR) Molecular Response RatesFrom Start of the Study up to End of Study (approximately up to 19 Months)

Molecular response was defined as major (≤ 0.1% on the International Scale) and complete \[absence of fusion gene of the BCR and ABL genes (BCR-ABL) on an quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay with a sensitivity of at least 4.5 logs below baseline\].

BCR-ABL Mutations of Participants at Study Entry and, in Responding Participants and at the Time of Disease ProgressionFrom Start of the Study up to End of Study (approximately up to 19 Months)

BCR-ABL messenger ribose nucleic acid (mRNA) expression (molecular response) was performed by quantitative polymerase chain reaction (qPCR) and mutational analysis was performed by direct sequencing technology, and both analyses were performed by Genzyme.

Time to Peak Concentration (Tmax) of PanobinostatPre-dose, and 0.25, 1-2, 3-4, 24, and 48 hours post-dose on Day 1

Time to reach peak or maximum plasma drug concentration following drug administration. Tmax will be reported in units of hour (hr).

Progression Free Survival TimeFrom Start of the Study up to End of Study (approximately up to 19 Months)

Progression-free survival time is defined as the time from the treatment start to the first documentation of the disease progression or the date of death, whichever occurs first

Maximum Plasma Concentration (Cmax) of PanobinostatPre-dose, and 0.25, 1-2, 3-4, 24, and 48 hours post-dose on Day 1

Cmax is defined as the Maximum (peak) plasma drug concentration after single dose administration. Cmax will be reported in units of nanogram/milliliter (ng/ML).

Last Observed Plasma Concentration (Clast) of PanobinostatPre-dose, and 0.25, 1-2, 3-4, 24, and 48 hours post-dose on Day 1

Clast is defined as the Last observed (quantifiable) plasma concentration at last sampling time.

Time of Clast (Tlast) of PanobinostatPre-dose, and 0.25, 1-2, 3-4, 24, and 48 hours post-dose on Day 1

Time of last sampling point. Tlast will be reported in units of hr

QT Interval (QTc) in Participants Receiving Oral Panobinostat at Baseline and Change From Baseline to Extreme ValueFrom Start of the Study up to End of Study (approximately up to 19 Months)

QTc monitoring was performed on specified days (Cycle1: Day1, 5 and 26), as well as a single pre-dose ECG once weekly during Cycle1: Week2 and Week3, Cycle2, and all subsequent cycles. Patient eligibility was ensured by a screening QTcF interval calculated by eResearchTechnology(eRT) prior to the baseline assessments. Treatment decisions were based on QTc determined by the automated reading at the investigational site (commonly used the Bazett's correction,QTcB) or measured and calculated by trained personnel at the site. Dosing relied on the investigator's assessment of the 6 baseline ECGs (the average of the 6pre-dose QTc intervals) performed prior to Cycle1/Day1 dosing, of the 3pre-dose ECGs during Cycle1:Day5 and 26, and of the single pre-dose ECGs performed once weekly for the remaining weeks of Cycle1 and subsequent cycles. The Baseline and Change From Baseline to Extreme Value QTcF interval for analysis was calculated by eRT based on the 6 baseline ECGs obtained on Cycle1/Day1.

Safety and Tolerability Profile of Oral PanobinostatFrom Start of the Study up to 28 Days After the last dose of Study Drug (approximately up to 19 Months)

Adverse events (AEs) are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events (SAEs) are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.

Trial Locations

Locations (1)

Novartis Investigative Site

🇩🇪

Munich, Germany

© Copyright 2025. All Rights Reserved by MedPath